Outcome of COVID-19 infection in patients on antihypertensives: A cross-sectional study

doi:10.5492/wjccm.v13.i3.96882

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-5)

Sum=0

Sep 9, 2024 (publication date) through Aug 30, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Critical Care Medicine

ISSN

2220-3141

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Crit Care Med. Sep 9, 2024; 13(3): 96882
Published online Sep 9, 2024. doi: 10.5492/wjccm.v13.i3.96882

Table 2 Complication, severity, and outcome frequency among the study population

Parameter	Total population, n = 260	Nonhypertensive, n = 60	ACEI/ARB, n = 62	Calcium channel blockers, n = 64	ACEI/ARB + CCB, n = 60	Beta-blockers, n = 14	P value
Pneumonia	8 (3.1)	-	3 (4.8)	4 (6.2)	1 (1.7)	-	0.235
ARDS	30 (11.5)	-	9 (14.5)	11 (17.2)¹	8 (13.3)	2 (14.3)	0.031
MODS	4 (1.5)	-	1 (1.6)	2 (3.1)	1 (1.7)	-	0.694
AKI	13 (5)	1 (1.7)	1 (1.6)	6 (9.4)	3 (5)	2 (14.3)	0.091
Renal failure	12 (4.6)	-	1 (1.6)	5 (7.8)	5 (8.3)	1 (7.1)	0.101
MoHFW severity
Asymptomatic	44 (16.9)	16 (26.7)	6 (9.7)	12 (18.8)	8 (13.3)	2 (14.3)	0.003
Mild	104 (40)	33 (55)	23 (37.1)	23 (35.9)	17 (28.3)	8 (57.1)
Moderate	33 (12.7)	5 (8.3)	11 (17.7)	6 (9.4)	9 (15)	2 (14.3)
Severe	79 (30.4)	6 (10)	22 (35.5)	23 (35.9)	26 (43.3)²	2 (14.3)
WHO grade
Asymptomatic	44 (16.9)	16 (26.7)	6 (9.7)	12 (18.8)	8 (13.3)	2 (14.3)	0.006
Mild	104 (40)	33 (55)	23 (37.1)	23 (35.9)	17 (28.3)	8 (57.1)
Moderate	33 (12.7)	5 (8.3)	11 (17.7)	6 (9.4)	9 (15)	2 (14.3)
Severe	41 (15.8)	5 (8.3)	12 (19.4)	9 (14.1)	15 (25)	-
Critical	38 (14.6)	1 (1.7)	10 (16.1)	14 (21.9)¹	11 (18.3)	2 (14.3)
ICU intervention	46 (17.7)	1 (1.7)	13 (21)	18 (28.1)¹	12 (20)	2 (14.3)	0.003
Death	24 (9.2)	-	4 (6.5)	12 (18.8)¹	7 (11.7)	1 (7.1)	0.007

¹Significant difference between the CCB group and others.

²Significant difference between the ACEI/ARB + CCB group and others.

Data are n (%). ACEI: Angiotensin-converting enzyme inhibitor; AKI: Acute kidney injury; ARB: Angiotensin receptor blocker; ARDS: Acute respiratory distress syndrome; CCB: Calcium channel blocker; ICU: Intensive care unit; MODS: Multiple organ dysfunction syndrome; MoHFW: Ministry of Health and Family Welfare; WHO: World Health Organization.

Citation: Varatharajan S, Bohra GK, Bhatia PK, Khichar S, Meena M, Palanisamy N, Gaur A, Garg MK. Outcome of COVID-19 infection in patients on antihypertensives: A cross-sectional study. World J Crit Care Med 2024; 13(3): 96882
URL: https://www.wjgnet.com/2220-3141/full/v13/i3/96882.htm
DOI: https://dx.doi.org/10.5492/wjccm.v13.i3.96882